Lipid Nanoparticles for Gene Therapy Market Research 2024: Gene Therapy Sales are Projected to Exceed $10bn by 2027 - LNPs have Gained Popularity as Carriers for Gene Therapies
18 sept. 2024 09h05 HE
|
Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy - Lipid nanoparticles" report has been added to ResearchAndMarkets.com's offering.This report discusses the developing trend and...
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
18 sept. 2024 01h00 HE
|
VALNEVA
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
17 sept. 2024 07h30 HE
|
BridgeBio Pharma, Inc.
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial...
InterDigital Wins Two CSI Awards for Best Immersive Video and Video Processing Technology
16 sept. 2024 08h30 HE
|
InterDigital, Inc.
InterDigital awarded CSI Awards for contributions to MPEG immersive standards and Advanced HDR solutions
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
16 sept. 2024 08h30 HE
|
Adaptive Research Inc
BAMF Health and Adaptive Research announced a strategic partnership to increase physician participation and patient enrollment in clinical trials.
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
16 sept. 2024 07h00 HE
|
Can-Fite BioPharma Ltd.
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
13 sept. 2024 02h30 HE
|
VALNEVA
Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its...
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
12 sept. 2024 16h05 HE
|
VALNEVA
Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject...
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
11 sept. 2024 12h07 HE
|
Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.